HCWB insider trading
NasdaqCM HealthcareHCW Biologics Inc.: insider trade history from SEC Form 4 filings.
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, an immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecules. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Company website: www.hcwbiologics.com
HCWB insider activity at a glance
FilingIQ tracks 115 insider transactions for HCWB in filings since Jul 23, 2021. The most recent transaction is dated Jul 29, 2026.
Across the full history, 91 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on HCWB insider trades is 62.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest HCWB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading HCWB
Frequently asked
- How many insider trades does FilingIQ track for HCWB?
- FilingIQ tracks 115 Form 4 insider transactions for HCWB (HCW Biologics Inc.), covering filings from Jul 23, 2021 onwards. 3 of those are dated within the last 90 days.
- Are HCWB insiders net buyers or net sellers?
- Across the full Form 4 history for HCWB, 91 transactions (79%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does HCWB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is HCWB in?
- HCW Biologics Inc. (HCWB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $15.68M.
Methodology & sources
Every HCWB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.